Law360, New York (March 21, 2011, 4:09 PM ET) -- The U.S. Supreme Court on Monday declined to take up Mylan Inc.'s argument that an appeals court incorrectly barred it from making generic versions of two hypertension drugs by applying a rigid test for a patent's obviousness.
In denying Mylan's Dec. 8 petition for writ of certiorari, the high court let stand the U.S. Court of Appeals for the Federal Circuit's September decision barring Mylan from making generic versions of Daiichi Sankyo Co Ltd.'s Benicar and Azor until a patent for the drugs expires in 2016....
High Court Won't Hear Mylan IP Fight Over Benicar
To view the full article, take a free trial now.
